We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Anti-adenoviral effect of anti-HIV agents in vitro in serotypes inducing keratoconjunctivitis.
- Authors
Eiichi Uchio; Aki Fuchigami; Kazuaki Kadonosono; Akio Hayashi; Hiroaki Ishiko; Koki Aoki; Shigeaki Ohno
- Abstract
Abstract Background  Around one million people are affected by adenoviral keratoconjunctivitis a year in Japan, and it is recognized as one of the major pathogens of ophthalmological nosocomial infection worldwide. Although cidofovir can be used systemically for immunocompromised patients with disseminated adenoviral infection, no specific anti-adenoviral agent has been established for the treatment of adenoviral infection. We evaluated the anti-adenoviral effect of anti-HIV (human immunodeficiency virus) agents in this study. Methods  Five anti-HIV agents (zalcitabine, stavudine, nevirapine, indinavir and amprenavir) were subjected to in vitro evaluation. A549 cells were used for viral cell culture, and adenovirus serotypes 3, 4, 8, 19 and 37 were used. After calculating CC50 (50% cytotoxic concentration) of each agent by MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) method, we cultured adenovirus with the agents for seven days and quantitatively measured extracted adenoviral DNA by real-time PCR. Results  Among the anti-HIV drugs, zalcitabine and stavudine, both nucleoside reverse transcriptase inhibitors, showed significant anti-adenoviral activity. In contrast, nevirapine, a non-nucleoside reverse transcriptase inhibitor, and indinavir and amprenavir, which are both protease inhibitors, were ineffective against adenovirus. Conclusions  These results indicate that zalcitabine and stavudine are possible candidates for the local and systemic treatment of adenoviral infection, and the anti-adenoviral effect might depend on the pharmacological properties of anti-HIV agents. The chemical properties on the clinical safety for systemic and local application need to be determined in order to for these drugs to be accepted for the treatment of adenovirus in clinical settings.
- Subjects
ANTI-infective agents; HIV infections; KERATOCONJUNCTIVITIS; NOSOCOMIAL infections
- Publication
Graefe's Archive of Clinical & Experimental Ophthalmology, 2007, Vol 245, Issue 9, p1319
- ISSN
0721-832X
- Publication type
Article
- DOI
10.1007/s00417-006-0523-z